In spite of the fact that MacFarlane is not subject to U.S. law he must necessarily have a confidentiality agreement with the company and he is bound by that. He would not want to put himself in the position of breaching confidentiality.
PIs sign NDAs and what you proposed would indeed be covered under them. He can discuss only what has already been revealed by the company, which is a public entity. MacFarlane could be sued by the company if it comes to regulatory harm and would lose his reputation as a reliable PI for any CRO or biotech.